Cytolysis of target cells by superantigen conjugates inducing T-cell activation

US6962694B1 · kind B1 · utility

Assignee

• Active Biotech AB · SE

Inventors

• Morten Soegaard
• Lars Abrahmsen · Bromma, SE
• Peter Lando · Malmö, SE
• Goran Forsberg · Karlstad, SE
• Terje Kalland · Arese, IT
• Mikael Dohlsten · Lund, SE

Key dates

• Filing date: Jul 21, 1998
• Grant date: Nov 8, 2005
• Expiry date: Jul 21, 2018

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/035
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A method for inactivating target cells in the presence of T cells by bringing the two types of cells in contact with a superantigen (SAG) in the presence of an immune modulator, characterized in that at least one of the superantigen and the immune modulator is in the form of a conjugate between a “free” superantigen (Sag) and a moiety targeting the conjugate to the target cells. A superantigen conjugate complying with the formula (1) (T)x(Sag)y(IM)z; a) T is a targeting moiety, Sag corresponds to a free superantigen, IM is an immune modulator that is not a superantigen and T, Sag and IM are linked together via organic linkers B; b) x, y and z are integers that typically are selected among 0-10 and represent the number of moieties T, Sag and IM, respectively, in a given conjugate molecule, with the provision that y>0 and also one or both of x and z>0. The superantigen conjugate is preferably a triple fusion protein. A targeted immune modulator, characterized in that it is a conjugate between a targeting moiety (T″′) and a modified immune modulator (IM″′). The conjugate complies with a formula analogous to formula (1) except for the imperative presence of the modified immune modulato…